Genome-wide by environment interaction studies of depressive symptoms and psychosocial stress in UK Biobank and Generation Scotland

Aleix Arnau-Soler, Erin Macdonald-Dunlop, Mark J. Adams, Toni-Kim Clarke, Donald J. MacIntyre, Keith Milburn, Lauren Navrady, Generation Scotland, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Caroline Hayward, Andrew M. McIntosh and Pippa A. Thomson

Abstract
Stress is associated with poorer physical and mental health. To improve our understanding of this link, we performed genome-wide association studies (GWAS) of depressive symptoms and genome-wide by environment interaction studies (GWEIS) of depressive symptoms and stressful life events (SLE) in two UK population-based cohorts (Generation Scotland and UK Biobank). No SNP was individually significant in either GWAS, but gene-based tests identified six genes associated with depressive symptoms in UK Biobank (DCC, ACSS3, DRD2, STAG1, FOXP2 and KYNU; $p < 2.77 \times 10^{-6}$). Two SNPs with genome-wide significant GxE effects were identified by GWEIS in Generation Scotland: rs12789145 (53-kb downstream PIWIL4; $p = 4.95 \times 10^{-9}$; total SLE) and rs17070072 (intronic to ZCCHC2; $p = 1.46 \times 10^{-8}$; dependent SLE). A third locus upstream CYLC2 (rs12000047 and rs12005200, $p < 2.00 \times 10^{-5}$; dependent SLE) when the joint effect of the SNP main and GxE effects was considered. GWEIS gene-based tests identified: MTNR1B with GxE effect with dependent SLE in Generation Scotland; and PHF2 with the joint effect in UK Biobank ($p < 2.77 \times 10^{-6}$). Polygenic risk scores (PRSs) analyses incorporating GxE effects improved the prediction of depressive symptom scores, when using weights derived from either the UK Biobank GWAS of depressive symptoms ($p = 0.01$) or the PGC GWAS of major depressive disorder ($p = 5.91 \times 10^{-3}$). Using an independent sample, PRS derived using GWEIS GxE effects provided evidence of shared aetiologies between depressive symptoms and schizotypal personality, heart disease and COPD. Further such studies are required and may result in improved treatments for depression and other stress-related conditions.

Introduction
Mental illness results from the interplay between genetic susceptibility and environmental risk factors. Previous studies have shown that the effects of environmental factors on traits may be partially heritable and moderated by genetics. Major depressive disorder (MDD) is the most common psychiatric disorder with a lifetime prevalence of approximately 14% globally and with a heritability of approximately 37%. There is strong evidence for the role of stressful life events (SLEs) as risk factor and trigger for...
of, environments 2,37. Genetic factors predisposing to through genetic in relation denotes a genetic mediation of associations gene homogeneous European ancestry.

Interaction between polygenic risk of MDD and recent SLE are reported to increase liability to depressive symptoms4,16, validating the implementation of genome-wide approaches to study GxE in depression. Most GxE studies for MDD have been conducted on candidate genes, or using polygenic approaches to a wide range of environmental risk factors, with some contradictory findings28–32. Incorporating knowledge about recent SLE into GWAS may improve our ability to detect risk variants in depression otherwise missed in GWAS33. To date, three studies have performed genome-wide by environment interaction studies (GWEIS) of MDD and SLE34–36, but this is the first study to perform GWEIS of depressive symptoms using adult SLE in cohorts of relatively homogeneous European ancestry.

Interpretation of GxE effects may be hindered by gene–environment correlation. Gene–environment correlation denotes a genetic mediation of associations through genetic influences on exposure to, or reporting of, environments2,37. Genetic factors predisposing to MDD may contribute to exposure and/or reporting of SLE38. To tackle this limitation, measures of SLE can be broken down into SLE likely to be independent of a respondent’s own behaviour and symptoms, or into dependent SLE, in which participants may play an active role exposure to SLE39,40. Different genetic influences, including a higher heritability, are reported for dependent SLE compared to independent SLE38,41–44, suggesting that whereas GxE driven by independent SLE is likely to reflect a genetic moderation of associations between SLE and depression, GxE driven by dependent SLE may result from a genetic mediation of the association through genetically driven personality or behavioural traits. To test this, we analysed dependent and independent SLE scores separately in Generation Scotland (GS).

Stress contributes to many human conditions, with evidence of genetic vulnerability to the effect of SLE45. Therefore, genetic stress-response factors in MDD may also underlie the aetiology of other stress-linked disorders with which MDD is often comorbid46,47 (e.g., cardiovascular diseases48, diabetes49, chronic pain50 and inflammation51). We tested the hypothesis that pleiotropy and shared aetiology between mental and physical health conditions may be due in part to genetic variants underlying SLE effects in depression.

In this study, we conduct GWEIS of depressive symptoms incorporating data on SLE in two independent UK-based cohorts. We aimed to: (i) identify loci associated with depressive symptoms through genetic response to SLE; (ii) study dependent and independent SLE to support a contribution of genetically mediated exposure to stress; (iii) assess whether GxE effects improve the proportion of phenotypic variance in depressive symptoms explained by genetic additive main effects alone; and (iv) test for a significant overlap in the genetic aetiology of the response to SLE and mental and physical stress-related phenotypes.

Materials and methods
The core workflow of this study is summarised in Fig. 1.

Cohort descriptions
GS
GS is a family-based population cohort representative of the Scottish population52. At baseline, blood and salivary DNA samples were collected, stored and genotyped at the Wellcome Trust Clinical Research Facility, Edinburgh. Genome-wide genotype data were generated using the Illumina HumanOmniExpressExome-8 v1.0 DNA Analysis BeadChip (San Diego, CA, USA) and Infinium chemistry53. The procedures and details for DNA extraction and genotyping have been extensively described elsewhere54,55. In total, 21,525 participants were re-contacted to participate in a follow-up mental health study (Stratifying Resilience and Depression Longitudinally, STRADL), of which 8541 participants responded providing updated measures in psychiatric symptoms and SLE through self-reported mental health questionnaires56. Samples were excluded if: they were duplicate samples, had diagnoses of bipolar disorder, no SLE data (non-respondents), were population outliers (mainly non-Caucasians and Italian ancestry subgroup), had sex mismatches or were missing >2% of genotypes. Single nucleotide polymorphisms (SNPs) were excluded if: missing >2% of genotypes, Hardy–Weinberg equilibrium test p < 1 × 10⁻⁶, or minor allele frequency <1%. Further details of the GS and STRADL cohort are available elsewhere52,56–58. All components of GS and STRADL obtained ethical approval from the Tayside Committee on Medical Research Ethics on behalf of the NHS (reference 05/s1401/89). After quality control, individuals were filtered by degree of relatedness (pi-hat < 0.05), maximising retention of those individuals reporting a higher number of SLE. The final dataset comprised data on 4919 unrelated individuals (1929 men; 2990 women) and 560,351 SNPs.

Independent GS datasets
Additional datasets for a range of stress-linked medical conditions and personality traits were created from GS (N
= 21,525) excluding respondents and their relatives (N = 5724). Following the same quality control criteria detailed above, we maximised unrelated non-respondents for retention of cases, or proxy cases (see below), to maximise the information available for each phenotype. This resulted in independent datasets with unrelated individuals for each trait. Differences between respondents and non-respondents are noted in the figure legend of Table 1.

UK Biobank (UKB)

This study used data from 99,057 unrelated individuals (47,558 men; 51,499 women) from the initial release of UKB genotyped data (released 2015; under UKB project 4844). Briefly, participants were removed based on UKB genomic analysis exclusion, non-white British ancestry, high missingness, genetic relatedness (kinship coefficient > 0.0442), QC failure in UK BiLEVE study and gender mismatch. GS participants and their relatives were excluded and GS SNPs imputed to a reference set combining the UK10K haplotype and 1000 Genomes Phase 3 reference panels. After quality control, 1,009,208 SNPs remained. UKB received ethical approval from the NHS National Research Ethics Service North West (reference: 11/NW/0382). Further details on UKB cohort description, genotyping, imputation and quality control are available elsewhere.

All participants provided informed consent.

Phenotype assessment

SLEs

GS participants reported SLE experienced over the preceding 6 months through a self-reported brief life events questionnaire based on the 12-item list of threatening experiences (Supplementary Table 1). The total number of SLE reported (TSLE) consisted of the number of ‘yes’ responses. TSLE were subdivided into SLE dependent on an individual’s own behaviour (DSLE) and independent SLE (ISLE).
potentially dependent or secondary to an individual’s own behaviour (DSLE, questions 6–11 in Supplementary Table 1a), and independent SLE (ISLE, questions 1–5 in Supplementary Table 1a; pregnancy item removed) following Brugha et al.\textsuperscript{39,40}. Thus, three SLE measures (TSLE, DSLE and ISLE) were constructed for GS. UKB

| Trait                                                                 | N      | Males/females | N SNPs  | N Cases | N Controls |
|-----------------------------------------------------------------------|--------|---------------|---------|---------|------------|
| Alzheimer (R)                                                         | 3377   | 1475/1903     | 560,622 | 655     | 2722       |
| Asthma                                                                | 3390   | 1500/1890     | 560,569 | 555     | 2835       |
| Asthma (R)                                                            | 3375   | 1470/1905     | 560,432 | 910     | 2465       |
| Bowel cancer (R)                                                      | 3386   | 1495/1891     | 560,630 | 672     | 2714       |
| Breast cancer                                                         | 3388   | 1486/1902     | 560,611 | 83      | 3305       |
| Breast cancer (R)                                                     | 3386   | 1482/1904     | 560,579 | 564     | 2822       |
| Chronic obstructive pulmonary disease                                 | 3387   | 1496/1891     | 560,591 | 73      | 3314       |
| Chronic obstructive pulmonary disease (R)                             | 3387   | 1474/1913     | 560,620 | 553     | 2834       |
| Depression                                                            | 3385   | 1495/1890     | 560,584 | 483     | 2902       |
| Depression (R)                                                        | 3382   | 1506/1876     | 560,514 | 731     | 2651       |
| Diabetes                                                              | 3388   | 1497/1891     | 560,469 | 185     | 3203       |
| Diabetes (R)                                                          | 3389   | 1481/1908     | 560,584 | 1144    | 2245       |
| Heart disease                                                         | 3392   | 1504/1888     | 560,526 | 212     | 3180       |
| Heart disease (R)                                                     | 3377   | 1483/1894     | 560,479 | 2254    | 1123       |
| High blood pressure                                                   | 3402   | 1501/1901     | 560,508 | 729     | 2673       |
| High blood pressure (R)                                               | 3372   | 1464/1908     | 560,569 | 1901    | 1471       |
| Hip fracture                                                          | 3388   | 1489/1899     | 560,572 | 421     | 2967       |
| Lung cancer (R)                                                       | 3379   | 1492/1887     | 560,600 | 798     | 2581       |
| Osteoarthritis                                                        | 3395   | 1486/1909     | 560,640 | 411     | 2984       |
| Osteoarthritis (R)                                                    | 3383   | 1466/1917     | 560,516 | 961     | 2422       |
| Parkinson                                                             | 3388   | 1488/1900     | 560,590 | 236     | 3152       |
| Prostate cancer (R)                                                   | 3381   | 1495/1886     | 560,570 | 329     | 3052       |
| Rheumatoid arthritis                                                  | 3387   | 1490/1897     | 560,618 | 93      | 3294       |
| Rheumatoid arthritis (R)                                              | 3380   | 1487/1893     | 560,543 | 765     | 2615       |
| Stroke                                                                | 3387   | 1492/1895     | 560,613 | 81      | 3306       |
| Stroke (R)                                                            | 3385   | 1463/1922     | 560,478 | 1506    | 1879       |
| Neuroticism\textsuperscript{a}                                        | 3421   | 1521/1900     | 560,484 | -       | -          |
| Extraversion\textsuperscript{a}                                       | 3420   | 1520/1900     | 560,476 | -       | -          |
| Schizotypal personality\textsuperscript{a}                           | 2386   | 1065/1321     | 560,369 | -       | -          |
| Mood disorder\textsuperscript{a}                                      | 2307   | 1040/1267     | 560,318 | -       | -          |

Samples were maximised for retention of cases to maximise the information available for each trait. There was no preferential selection of relatives in pairs for quantitative phenotypes, in order to retain the underlying distribution. All individuals involved in the datasets listed above were non-respondents to the GS follow-up study. Compared with individuals included at GS GWEIS (respondents in GS follow-up), non-respondents were significantly: younger, from more socioeconomically deprived areas, generally less healthier and wealthier. Non-respondents were more likely to smoke, and less likely to drink alcohol, although they consumed more units per week, compared with respondents. At GS baseline, non-respondents experienced more psychological distress and reported higher scores in symptoms of GHQ-depression and GHQ-anxiety than respondents\textsuperscript{56}

The total target sample size (N), number of males and females in N, number of SNPs (N SNPs) in target sample size N, the number of SNPs used as predictors after clumping step range between 90,650 and 91,000. The number of cases and controls in the independent target sample is indicated for binary phenotypes only. Samples were mapping by proxy approach was used (i.e., where first-degree relatives of individuals with the disease were considered proxy cases and included into the group of cases) are indicated by (R)

GS Generation Scotland, GWEIS genome-wide by environment interaction studies, GHQ General Health Questionnaire

\textsuperscript{a}Assessed through self-reported questionnaires
participants were screened for ‘illness, injury, bereavement and stress’ (Supplementary Table 1b) over the previous 2 years using six items included in the UKB Touchscreen questionnaire. A score reflecting SLE reported in UKB (TSLEUKB) was constructed by summing the number of ‘yes’ responses.

**Psychological assessment**

GS participants reported whether their current mental state over the preceding 2 weeks differed from their typical state using a self-administered 28-item scaled version of the General Health Questionnaire (GHQ)66–67. Participants rated the degree and severity of their current symptoms with a four-point Likert scale (following Goldberg et al.67). A final log-transformed GHQ was used to detect altered psychopathology and thus, assess depressive symptoms as results of SLE. In UKB participants, current depressive symptoms over the preceding 2 weeks were evaluated using four psychometric screening items (Supplementary Table 2), including two validated and reliable questions for screening depression68, from the Patient Health Questionnaire (PHQ) validated to screen mental illness69,70. Each question was rated in a four-point Likert scale to assess impairment/severity of symptoms. Due to its skewed distribution, a four-point PHQ score was formed from PHQ (0 = 0; 1 = 1–2; 2 = 3–5; 3 = 6 or more) to create a more normal distribution.

**Stress-related traits**

Targeted GS stress-related phenotypes and sample sizes are shown in Table 1 and detailed elsewhere52. These conditions were selected from literature review based on previous evidence of a link with stress45 (see also Supplementary Material: third section). Furthermore, we created additional independent samples using mapping by proxy, where individuals with a self-reported first-degree relative with a selected phenotype were included as proxy cases. This approach provides greater power to detect susceptibility variants in traits with low prevalence71.

**Statistical analyses**

**SNP-heritability and genetic correlation**

A restricted maximum likelihood approach was applied to estimate SNP-heritability ($h^2_{SNP}$) of depressive symptoms and self-reported SLE measures, and within samples bivariate genetic correlation between depressive symptoms and SLE measures using GCTA72.

**GWAS analyses**

GWAS were conducted in PLINK73. In GS, age, sex and 20 principal components (PCs) were fitted as covariates. In UKB, age, sex and 15 PCs recommended by UKB were fitted as covariates. The genome-wide significance threshold was $p = 5 \times 10^{-8}$.

**GWEIS analyses**

GWEIS were conducted on GHQ (the dependent variable) for TSLE, DSLE and ISLE in GS and on PHQ for TSLEUKB in UKF fitting the same covariates detailed above to reduce error variance. GWEIS were conducted using an R plugin for PLINK73 developed by Almli et al.74 (https://epstein-software.github.io/robust-joint-interaction). This method implements a robust test that jointly considers SNP and SNP–environment interaction effects from a full model ($Y \sim \beta_0 + \beta_{SNP} + \beta_{SLE} + \beta_{SNP \times SLE} + \beta_{Covariates}$) against a null model where both the SNP and SNP×SLE effects equal 0, to assess the joint effect (the combined additive main and GxE genetic effect at a SNP) using a nonlinear statistical approach that applies Huber–White estimates of variance to correct possible inflation due to heteroscedasticity (unequal variances across exposure levels). This robust test should reduce confounding due to differences in variance induced by covariate interaction effects if present75. Additional code was added (courtesy of Prof. Michael Epstein;74 Supplementary Material) to generate beta-coefficients and the $p$-value of the GxE term alone. In UKB, correcting for 1,009,208 SNPs and one exposure, we established a Bonferroni-adjusted threshold for significance at $p = 2.47 \times 10^{-8}$ for both joint and GxE effects. In GS, correcting for 560,351 SNPs and three measures of SLE we established a genome-wide significance threshold of $p = 2.97 \times 10^{-8}$.

**Post-GWAS/GWEIS analyses**

GWAS and GWEIS summary statistics were analysed using FUMA76 including: gene-based tests, functional annotation, gene prioritisation and pathway enrichment (Supplementary Material).

**Polygenic profiling and prediction**

Polygenic risk scores (PRSs) weighting by GxE effects (PRS$_{GxE}$) were generated using PRSice-277 (Supplementary Material) in GS using GxE effects from UKB-GWEIS. In UKB, PRS$_{GxE}$ were constructed using GxE effects from all three GS-GWEIS (TSLE, DSLE and ISLE as exposures) independently. PRS were also weighted in both samples using either UKB-GWAS or GS-GWAS statistics (PRS$_D$), and summary statistics from Psychiatric Genetic Consortium (PGC) MDD-GWAS (released 2016; PRS$_{MDD}$) that excluded GS and UKB individuals when required ($N_{noGS} = 155,866$; $N_{noUKB} = 138,884$). Furthermore, we calculated PRS weighted by the joint effects (the combined additive main and GxE genetic effects; PRS$_{Joint}$) from either the UKB-GWEIS or GS-GWEIS. PRS predictions of depressive symptoms were permuted 10,000 times. Multiple regression models fitting PRS$_{GxE}$ and PRS$_{MDD}$ and both PRS$_{GxE}$ and PRS$_D$ were tested. All models were adjusted by same covariates used in GWAS/
GWEIS. Null models were estimated from the direct effects of covariates alone. The predictive improvement of combining PRSGxE and PRSMD/PTRS effects over PRSMD/PTRS effects alone was tested for significance using the likelihood ratio test (LRT).

Prediction of PRSD, PRSGxE and PRSJoint of stress-linked traits was adjusted by age, sex, and 20 PCs; and permuted 10,000 times. Empirical- 

\[ p \leq 0.16 \times 10^{-3} \]  

The predictive improvement of fitting PRSGxE combined with PRSD and covariates over prediction of a phenotype using the PRSD effect alone with covariates was assessed using LRT, and \( LRT-p \)-values adjusted by FDR (conservative threshold at \( LRT-p = 8.35 \times 10^{-6} \)).

**Results**

**Phenotypic and genetic correlations**

Depressive symptom scores and SLE measures were positively correlated in both UKB (\( r^2 = 0.22, p < 2.2 \times 10^{-15} \)) and GS (TSLE\( r^2 = 0.21, p = 1.69 \times 10^{-52} \); DSLE\( r^2 = 0.21, p = 8.59 \times 10^{-51} \); ISLE\( r^2 = 0.17, p = 2.33 \times 10^{-33} \)). Significant bivariate genetic correlation between depression and SLE scores was identified in UKB (\( r(\text{G}) = 0.72; p < 1 \times 10^{-5}, N = 50,000 \)), but not in GS (\( r(\text{G}) = 1, p = 0.056, N = 4919 \); Supplementary Table 3a).

**SNP-heritability (\( h^2_{\text{SNP}} \))**

In UKB, a significant \( h^2_{\text{SNP}} \) of PHQ was identified (\( h^2_{\text{SNP}} = 0.090; p < 0.001; N = 99,057 \)). This estimate remained significant after adjusting by TSLEUKB effect (\( h^2_{\text{SNP}} = 0.079; p < 0.001 \)), suggesting a genetic contribution unique to depressive symptoms. The \( h^2_{\text{SNP}} \) of TSLEUKB was also significant (\( h^2_{\text{SNP}} = 0.040, p < 0.001 \); Supplementary Table 3b). In GS, \( h^2_{\text{SNP}} \) was not significant for GHQ (\( h^2_{\text{SNP}} = 0.071, p = 0.165; N = 4919 \)). However, in an \textit{ad hoc} estimation from the baseline sample of 6751 unrelated GS participants (details in Supplementary Table 3b) we detected a significant \( h^2_{\text{SNP}} \) for GHQ (\( h^2_{\text{SNP}} = 0.135; p < 5.15 \times 10^{-5} \)), suggesting that the power to estimate \( h^2_{\text{SNP}} \) in GS may be limited by sample size. Estimates were not significant for either TSLE (\( h^2_{\text{SNP}} = 0.061, p = 0.189 \); Supplementary Table 3b) or ISLE (\( h^2_{\text{SNP}} = 0.000, p = 0.5 \)), but \( h^2_{\text{SNP}} \) was significant for DSLE (\( h^2_{\text{SNP}} = 0.131, p = 0.029 \)), supporting a potential genetic mediation and gene–environment correlation.

**GWEIS of depressive symptoms**

No genome-wide significant SNPs were detected by GWAS in either cohort. Top findings (\( p < 1 \times 10^{-5} \)) are summarised in Supplementary Table 4. Manhattan and QQ plots are shown in Supplementary Figures 1-4. There was no evidence of genomic inflation (all \( \lambda_{1000} < 1.01 \)).

**Post-GWAS analyses**

Gene-based test identified six genes associated with PHQ using the UKB-GWAS statistics at genome-wide significance (Bonferroni-corrected \( p = 2.77 \times 10^{-6} \); \( DCC, p = 7.53 \times 10^{-8} \); \( DRD2, p = 6.55 \times 10^{-7} \); \( FOXP2, p = 2.09 \times 10^{-5} \); \( KYNU, p = 2.24 \times 10^{-6} \); Supplementary Figure 8). Prioritised genes based on position, expression quantitative trait loci (eQTL) and chromatin interaction mapping are detailed in Supplementary Table 5. No genes were detected in GS-GWAS gene-based test (Supplementary Figures 9). No tissue-specific enrichment was detected from GWAS in either cohort. Significant gene-sets and GWAS catalogue associations for UKB-GWAS are reported in Supplementary Table 6. These included the \textit{biological process}: positive regulation of long-term synaptic potentiation, and \textit{GWAS catalogue associations}: brain structure, schizophrenia, response to amphetamines, age-related cataracts (age at onset), fibrinogen, acne (severe), fibrinogen levels and educational attainment; all adjusted- \( p < 0.01 \). There was no significant gene-set enrichment from GS-GWAS.

**GWEIS of depressive symptoms**

Manhattan and QQ plots are shown in Supplementary Figures 1-4. There was no evidence of GWEIS inflation for either UKB or GS (all \( \lambda_{1000} < 1.01 \)). No genome-wide significant GWEIS associations were detected for SLE in UKB. GS-GWEIS using TSLE identified a significant GxE effect (\( p < 2.97 \times 10^{-8} \)) at an intragenic SNP on chromosome 11 (rs12789145, \( p = 4.95 \times 10^{-9}, \beta = 0.06, \) closest gene: \textit{PIWIL4}; Supplementary Figure 5), and using DSLE at an intronic SNP in \textit{ZCCHC2} on chromosome 18 (rs17070072, \( p = 1.46 \times 10^{-8}, \beta = -0.08; \) Supplementary Figure 6). In their corresponding joint effect tests, both rs12789145 (\( p = 2.77 \times 10^{-6} \)) and rs17070072 (\( p = 1.96 \times 10^{-6} \)) were significant. GWEIS for joint effect using DSLE identified two further significant SNPs on chromosome 9 (rs12000047, \( p = 2.00 \times 10^{-8}, \beta = -0.23; \) rs12005200, \( p = 2.09 \times 10^{-8}, \beta = -0.23, \) LD \( r^2 > 0.8, \) closest gene: \textit{CYLC2}; Supplementary Figure 7). None of these associations replicated in UKB (\( p > 0.05 \)), although the effect direction was consistent between cohorts for the SNP close to \textit{PIWIL1} and SNPs at \textit{CYLC2}. No SNP achieved genome-wide significant association in the GS-GWEIS using ISLE as exposure. Top GWEIS results (\( p < 1 \times 10^{-5} \)) are summarised in Supplementary Tables 7-10.

**Post-GWAS analyses: gene-based tests**

All results are shown in Supplementary Figures 10-17. Two genes were associated with PHQ using the joint effect from the UKB-GWEIS (\( ACSS3, p = 1.61 \times 10^{-6} \); \( PHF2, p = 2.28 \times 10^{-6} \); Supplementary Figure 11). ACSS3 was previously identified using the additive main effects,
whereas PHF2 was only significantly associated using the joint effects. Gene-based tests identified MTNRI1B as significantly associated with GHQ on the GS-GWEIS using DSLE in both GxE ($p = 1.53 \times 10^{-6}$) and joint effects ($p = 2.38 \times 10^{-6}$; Supplementary Tables 11-14). Post-GWEIS analyses: tissue enrichment

We prioritised genes based on position, eQTL and chromatin interaction mapping in brain tissues and regions. In UKB, prioritised genes using GxE effects were enriched for upregulated differentially expressed genes from adrenal gland (adjusted-$p = 3.58 \times 10^{-2}$). Using joint effects, prioritised genes were enriched on upregulated differentially expressed genes from artery tibial (adjusted-$p = 4.34 \times 10^{-2}$). In GS, prioritised genes were enriched: in upregulated differentially expressed genes from artery coronary (adjusted-$p = 4.55 \times 10^{-2}$) using GxE effects with DSLE; in downregulated differentially expressed genes from artery aorta tissue (adjusted-$p = 4.71 \times 10^{-2}$) using GxE effects with ISLE; in upregulated differentially expressed genes from artery coronary (adjusted-$p = 5.97 \times 10^{-3}$, adjusted-$p = 9.57 \times 10^{-3}$) and artery tibial (adjusted-$p = 1.05 \times 10^{-2}$, adjusted-$p = 1.55 \times 10^{-2}$) tissues using joint effects with both TSLE and DSLE; and in downregulated differentially expressed genes from lung tissue (adjusted-$p = 3.98 \times 10^{-2}$) and in up- and downregulated differentially expressed genes from the spleen (adjusted-$p = 4.71 \times 10^{-2}$) using joint effects with ISLE. There was no enrichment using GxE effect with TSLE.

Post-GWEIS analyses: gene-sets enrichment

Significant gene-sets and GWAS catalogue hits from GWEIS are detailed in Supplementary Tables 11-14, including for UKB Biocarta: GPCR pathway; Reactome: opioid signalling, neurotransmitter receptor binding and downstream transmission in the postsynaptic cell, transmission across chemical synapses, gastrin CREB signalling pathway via PKC and MAPK; GWAS catalogue: post bronchodilator FEV1/FVC ratio, migraine and body mass index. In GS, enrichment was seen using TSLE and DLSE for GWAS catalogue: age-related macular degeneration, myopia, urate levels and Heschl’s gyrus morphology; and using ISLE for biological process: regulation of transporter activity. All adjusted-$p < 0.01$.

Cross-cohort prediction

In GS, PRS$_D$ weighted by the UKB-GWAS of PHQ significantly explained 0.56% of GHQ variance (Empirical-$p < 1.10^{-5}$), similar to PRS$_{MDD}$ weighted by PGC MDD-GWAS ($R^2 = 0.78\%$, Empirical-$p < 1.10^{-4}$). PRS$_{GxE}$ weighted by the UKB-GWEIS GxE effects explained 0.15% of GHQ variance (Empirical-$p = 0.03$, Supplementary Table 15). PRS$_{GxE}$ fitted jointly with PRS$_{MDD}$ significantly improved prediction of GHQ ($R^2 = 0.93\%$,

$$\text{model } p = 6.12 \times 10^{-11}; \text{ predictive improvement of } 19\%,$$

$$\text{LRT}\text{-}p = 5.91 \times 10^{-3}\text{ compared with PRS}_{MDD} \text{ alone. Similar to PRS}_{GxE} \text{ with PRS}_D \text{ ($R^2 = 0.69\%$, model } p = 2.72 \times 10^{-8}; \text{ predictive improvement of } 23\%, \text{ LRT}\text{-}p = 0.01). PRS\text{joint weighted by the UKB-GWEIS also predicted GHQ ($R^2 = 0.58\%$, Empirical-$p < 1.10^{-4}$, although
the variance explained was significantly reduced compared with the model fitting PRS$_{\text{GxE}}$ and PRS$_D$ together ($LRT-p = 4.69 \times 10^{-7}$), suggesting that additive and GxE effects should be modelled independently for polygenic approaches (Fig. 2a).

In UKB (Fig. 2b), both PRS$_D$ weighted by the GS-GWAS of GHQ and PRS$_{\text{MDD}}$ significantly explained 0.04 and 0.45% of PHQ variance, respectively (both Empirical-$p < 1.10^{-4}$, Supplementary Table 15). PRS$_{\text{GxE}}$ derived from the GS-GWEIS GxE effect did not significantly predicted PHQ (TSLE-PRS$_{\text{GxE}}$ Empirical-$p = 0.382$; DSLE-PRS$_{\text{GxE}}$ Empirical-$p = 0.642$; ISLE-PRS$_{\text{GxE}}$ Empirical-$p = 0.748$). Predictive improvements using the PRS$_{\text{GxE}}$ effect fitted jointly with PRS$_{\text{MDD}}$ or PRS$_D$ were not significant (all $LRT-p > 0.08$). PRS$_{\text{Joint}}$ significantly predicted PHQ (TSLE-PRS$_{\text{Joint}}$: $R^2 = 0.032$%, Empirical-$p < 1.10^{-4}$; DSLE-PRS$_{\text{Joint}}$: $R^2 = 0.012$%, Empirical-$p = 4.3 \times 10^{-3}$; ISLE-PRS$_{\text{Joint}}$: $R^2 = 0.032$%, Empirical-$p < 1.10^{-4}$), although the variance explained was significantly reduced compared with the models fitting PRS$_{\text{GxE}}$ and PRS$_D$ together (all $LRT-p < 1.48 \times 10^{-3}$).

**Prediction of stress-related traits**

Prediction of stress-related traits in independent samples using PRS$_D$, PRS$_{\text{GxE}}$ and PRS$_{\text{Joint}}$ are summarised in Fig. 3a and Supplementary Table 16. Significant trait prediction after FDR adjustment (Empirical-$p < 6.16 \times 10^{-3}$, FDR-adjusted Empirical-$p < 0.05$) using both UKB and GS PRS$_D$ was seen for: depression status, neuroticism and schizotypal personality. PRS$_{\text{GxE}}$ weighted by the GS-GWEIS GxE effect using ISLE significantly predicted depression status mapped by proxy (Empirical-$p = 7.00 \times 10^{-4}$, FDR-adjusted Empirical-$p = 9.54 \times 10^{-3}$).

Nominally significant predictive improvements ($LRT-p < 0.05$) of fitting PRS$_{\text{GxE}}$ over the PRS$_D$ effect alone, using summary statistics generated from both UKB and GS were detected for schizotypal personality, heart diseases and chronic obstructive pulmonary disease (COPD) by proxy (Fig. 3b). PRS$_{\text{GxE}}$ weighted by GS-GWEIS GxE effect using ISLE significantly improved prediction over PRS$_D$ effect alone of depression status mapped by proxy after FDR adjustment ($LRT-p = 1.96 \times 10^{-4}$, FDR-adjusted $LRT-p = 2.35 \times 10^{-2}$).

**Discussion**

This study performs GWAS and incorporates data on recent adult SELEs into GWEIS of depressive symptoms, identifies new loci and candidate genes for the modulation of genetic response to SLE; and provides insights to help disentangle the underlying aetiological mechanisms increasing the genetic liability through SLE to both depressive symptoms and stress-related traits.

SNP-heritability of depressive symptoms ($h^2_{\text{SNP}} = 9$–13%), were slightly higher than previous estimates from African-American populations,$^{34}$ and over a third larger than estimates in MDD from European samples,$^{78}$ $h^2_{\text{SNP}}$ for PHQ in UKB (9.0%) remained significant after adjusting for SLE (7.9%). Thus, although some genetic contributions may be partially shared between depressive symptoms and reporting of SLE, there is still a relatively large genetic contribution unique to depressive symptoms. Significant $h^2_{\text{SNP}}$ of DSLE in GS (13%) and TSLE$_{\text{UKB}}$ in UKB (4%), which is mainly composed of dependent SLE items, were detected similar to previous studies (8 and 29%)$^{34,42}$. Conversely, there was no evidence for heritability of independent SLE. A significant bivariate genetic correlation between depressive symptoms and SLE ($r_G = 0.72$) was detected in UKB after adjusting for covariates, suggesting that there are shared common variants underlying self-reported depressive symptoms and SLE.

This bivariate genetic correlation was smaller than that estimated from African-American populations ($r_G = 0.97$; $p = 0.04$; $N = 7179$)$^{34}$. Genetic correlations between SLE measures and GHQ were not significant in GS ($N = 4919$; $r_G = 1$; all $p > 0.056$), perhaps due to a lack of power in this smaller sample.

Post-GWAS gene-based tests detected six genes significantly associated with PHQ ($DCC$, $ACSS3$, $DRD2$, $STAG1$, $FOXP2$ and $KYN1$). Previous studies have implicated these genes in liability to depression (see Supplementary Table 17), and three of them are genome-wide significant in gene-based tests from the latest meta-analysis of major depression that includes UKB ($DCC$, $p = 2.57 \times 10^{-14}$; $DRD2$, $p = 5.35 \times 10^{-14}$; and $KYN1$, $p = 2.38 \times 10^{-6}$; $N = 807,553$)$^{39}$. This supports the implementation of quantitative measures such as PHQ to detect genes underlying lifetime depression status.$^{80}$ For example, significant gene ontology analysis of the UKB-GWAS identified enrichment for positive regulation of long-term synaptic potentiation, and for previous GWAS findings of brain structure$^{81}$, schizophrenia$^{82}$ and response to amphetamines$^{83}$.

The key element of this study was to conduct GWEIS of depressive symptoms and recent SLE. We identified two loci with significant GxE effect in GS. However, none of these associations replicated in UKB ($p > 0.05$). The strongest association was using TSLE at 53-kb downstream of $PIWIL4$ (rs12789145). $PIWIL4$ is brain expressed and involved in chromatin modification$^{84}$, suggesting it may moderate the effects of stress on depression. It encodes HIWI2, a protein thought to regulate OTX2, that is critical for the development of forebrain and for coordinating critical periods of plasticity disrupting the integration of cortical circuits.$^{85,86}$ Indeed, an intronic SNP in $PIWIL4$ was identified as the strongest GxE signal in attention deficit hyperactivity disorder using mother’s warmth as environmental exposure.$^{87}$ The other significant GxE identified in our study was in $ZCCHC2$ using
DSLE. This zinc-finger protein is expressed in blood CD4+ T cells and is downregulated in individuals with MDD and in those resistant to treatment with citalopram. No GxE effect was seen using ISLE as exposure.

No significant locus or gene with GxE effect was detected in the UKB-GWEIS. Nevertheless, joint effects (the combined additive main and GxE genetic effects) identified two genes significantly associated with PHQ (ACSS3 and PHF2; see Supplementary Table 17). PHF2 was recently detected as genome-wide significant at the latest meta-analysis of depression. Notably, PHF2 paralogs have previously been linked with MDD through stress-response in three other studies. Joint effects analyses in GS also detected an additional significant association upstream CYLC2, a gene nominally associated ($p < 1 \times 10^{-5}$) with obsessive-compulsive disorder and Tourette's syndrome. Gene-based test from the GS-GWEIS identified a significant association with

---

**Fig. 3 Polygenic risk score (PRS) prediction in independent Generation Scotland (GS) datasets.** a) Heatmap illustrating PRS prediction of a wide range of traits from GS listed in the x axis (Table 1). (R) refers to traits using mapping by proxy approach (i.e., where first-degree relatives of individuals with the disease are considered proxy cases and included into the group of cases). Y axis shows the discovery sample and the effect used to weight PRS. Numbers in cells indicate the % of variance explained, also represented by colour scale. Significance is represented by asterixes according to the following significance codes: **$p < 0.01$; *$p < 0.05$; in grey Empirical-$p$-values after permutation (10,000 times) and in yellow FDR-adjusted Empirical-$p$-values. b) Predictive improvement by GxE effect in independent GS datasets. Heatmap illustrating the predictive improvement as a result of incorporating PRS$_{GxE}$ into a multiple model along with PRS$_D$ and covariates (full model), over a model fitting PRS$_D$ alone with covariates (null model), predicting a wide range of traits from GS listed in the x axis (Table 1). Covariates: age, sex and 20 PCs. (R) refers to traits using mapping by proxy approach (i.e., where first-degree relatives of individuals with the disease are consider proxy cases and included into the group of cases). PRS$_{GxE}$ are weighted by genome-wide by environment interaction studies (GWEIS) using GxE effects. PRS$_D$ were weighted by the genome-wide association studies (GWAS) of depressive symptoms additive main effects. The y axis shows the discovery sample used to weight PRS. Numbers in cells indicate the % of variance explained by the PRS$_{GxE}$, also represented by colour scale. Notice that those correspond to the PRS$_{GxE}$ predictions in Fig. 3a when PRS$_{GxE}$ are weighted by GxE effects. Significance was tested by likelihood ratio tests (LRT): full model including PRS$_D$ + PRS$_{GxE}$ vs. null model with PRS$_D$ alone (covariates adjusted). Significance is represented by asterixes according to the following significance codes: ***$p < 0.001$; **$p < 0.01$; *$p < 0.05$; in grey LRT-$p$-values and in yellow FDR-adjusted LRT-$p$-values.
MTNR1B, a melatonin receptor gene, using DSLE (both GxE and joint effect; Supplementary Table 17). Genes prioritised using GxE effects were enriched in differentially expressed genes from several tissues including the adrenal gland, which releases cortisol into the bloodstream in response to stress, thus playing a key role in the stress-response system, reinforcing a potential role of GxE in stress-related conditions.

The different instruments and sample sizes available make it hard to compare results between cohorts. Whereas GS contains deeper phenotyping measurements of stress and depressive symptoms than UKB, the sample size is much smaller, which may be reflected in the statistical power required to reliably detect GxE effects. Furthermore, the presence and size of GxE effects are dependent on their parameterisation (i.e., the measurement, scale and distribution of the instruments used to test such interaction)\(^9\). Thus, GxE may be incomparable across GWEIS due to differences in both phenotype assessment and stressors tested. Although our results suggest that both depressive symptom measures are correlated with lifetime depression status, different influences on depressive symptoms from the SLE covered across studies may contribute to lack of stronger replication. Instruments in GS cover a wider range of SLE and are more likely to capture changes in depressive symptoms as consequence of their short-term effects. Conversely, UKB could capture more marked long-term effects, as SLE were captured over 2 years compared with the 6 months in GS. New mental health questionnaires covering a wide range of psychiatric symptoms and SLE in the latest release of UKB data provides the opportunity to create similar measures to GS in the near future. Further replication in independent studies with equivalent instruments is required to validate our GWEIS findings. Despite these limitations and a lack of overlap in the individual genes prioritised from the two GWEIS, replication was seen in the predictive improvement of using PRS\(_{GxE}\) derived from the GWEIS GxE effects to predict stress-related phenotypes.

The third aim of this study was to test whether modelling GxE effects could improve predictive genetic models, and thus help to explain deviation from additive models and missing heritability for MDD\(^{45}\). Multiple regression models suggested that inclusion of PRS\(_{GxE}\) weighted by GxE effects could improve prediction of an individual’s depressive symptoms over use of PRS\(_{MDD}\) or PRS\(_{D}\) weighted by additive effects alone. In GS, we detected a predictive gain of 19% over PRS\(_{MDD}\) weighted by PGC MDD-GWAS, and a gain of 23% over PRS\(_{D}\) weighted by UKB-GWAS (Fig. 2a). However, these findings did not surpass stringent Bonferroni correction and could not be validated in UKB. This may reflect in the poor predictive power of the PRS generated from the much smaller GS discovery sample. The results show a noticeably reduced prediction using PRS\(_{Joint}\) weighted by joint effects, which suggests that the genetic architecture of stress-response is at least partially independent and differs from genetic additive main effects. Overall, our results from multiple regression models suggest that for polygenic approaches main and GxE effects should be modelled independently.

SLE effects are not limited to mental illness\(^{45}\). Our final aim was to investigate shared aetiology between GxE for depressive symptoms and stress-related traits. Despite the differences between the respondents and non-respondents (Table 1 legend), a significant improvement was seen in predicting depressive status when mapping by proxy cases using GxE effect from GS-GWEIS with independent SLE (FDR-adjusted LRT-\(p = 0.013\)), but not with dependent SLE. GxE effects using statistics generated from both discovery samples, despite the differences in measures, nominally improved the phenotypic prediction of schizotypal personality, heart disease and the proxy of COPD (LRT-\(p < 0.05\)). Other studies have also found evidence supporting a link between stress and depression in these phenotypes (see Supplementary Material for extended review) and suggest, for instance, potential pleiotropy between schizotypal personality and stress-response. Our findings point to a potential genetic component underlying a stress-response-depression-comorbidities link due, at least in part, to shared stress-response mechanisms. A relationship between SLE, depression and coping strategies such as smoking suggests that genetic stress-response may modulate adaptive behaviours such as smoking, fatty diet intake, alcohol consumption and substance abuse. This is discussed further in the Supplementary Material.

In this study, evidence for SNPs with significant GxE effects came primarily from the analyses of dependent SLE and not from independent SLE. This supports a genetic effect on probability of exposure to, or reporting of SLE, endorsing a gene–environment correlation. Chronic stress may influence cognition, decision making and behaviour eventually leading to higher risk taking\(^{46}\). These conditions may also increase sensitivity to stress among vulnerable individuals, including those with depression, who also have a higher propensity to report SLE, particularly dependent SLE\(^38\). A potential reporting bias in dependent SLE may be mediated as well by heritable behavioural, anxiety or psychological traits such as risk taking\(^{42,47}\). Furthermore, individuals vulnerable to MDD may behave in a manner that exposes them more frequently to high risk and stressful environments\(^14\). This complex interplay, reflected in the form of a gene–environment correlation effect, would hinder the interpretation of GxE effects from GWEIS as pure interactions. A mediation of associations between SLE and
depressive symptoms, through genetically driven sensitivity to stress, personality or behavioural traits would support the possibility of subtle genotype-by-genotype (GxG) interactions, or genotype-by-genotype-by-environment (GxGxE) interactions, contributing to depression\(^\text{96,99}\). In contrast, PRS prediction of the stress-related traits: schizotypal personality, heart disease and COPD, was primarily from derived weights using independent SLE, suggesting that a common set of variants moderate the effects of SLE across stress-related traits and that larger sample sizes will be required to detect the individual SNPs contributing to this. Thus, our findings suggest the inclusion of environmental information into GWAS to enhance the detection of relevant genes. The results of studying dependent and independent SLE support a contribution of genetically mediated exposure to and/or reporting of SLE, perhaps through sensitivity to stress as mediator.

This study emphasises the relevance of GxE in depression and human health in general and provides the basis for future lines of research.

Acknowledgements
See Supplementary Material: acknowledgements.

Author details
1Medical Genetics Section, University of Edinburgh, Centre for Genomic and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK. 2Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Teviot Place, Edinburgh, UK. 3Division of Psychiatry, Deanery of Clinical Sciences, University of Edinburgh, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK. 4Health Informatics Centre, University of Dundee, Dundee, UK. 5Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
accompanies this paper at (https://doi.org/10.1038/s41398-018-0360-y).

References
1. Plomin, R., Owen, M. & McCafflin, P. The genetic basis of complex human behaviors. Science 264, 1733–1739 (1994).
2. Kendler, K. S. & Eaves, L. J. Models for the joint effect of genotype and environment on liability to psychiatric illness. Am. J. Psychiatry 143, 279–289 (1986).
3. Kendler, K. S. & Baker, J. H. Genetic influences on measures of the environment: a systematic review. Psychol. Med. 37, 615–626 (2007).
4. Colodro-Conde, L. et al. A direct test of the diathesis-stress model for depression. Mol. Psychiatry 23, 1590–1596 (2017).
5. Luciano, M. et al. Shared genetic aetiology between cognitive ability and cardiovascular disease risk factors: Generation Scotland’s Scottish family health study. Intelligence 38, 304–313 (2010).
6. Kessler, R. C. & Bromet, E. J. The epidemiology of depression across cultures. Annu. Rev. Public Health 34, 119–138 (2013).
7. Sullivan, P. F., Neale, M. C. & Kendler, K. S. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 157, 1552–1562 (2000).
8. Hammer, C. Stress and depression. Annu. Rev. Clin. Psychol. 1, 293–319 (2005).
9. Kessler, R. C. The effects of stressful life events on depression. Annu. Rev. Psychol. 48, 191–214 (1997).
10. Kendler, K. S., Karkowski, L. M. & Prescott, C. A. Causal relationship between stressful life events and the onset of major depression. Am. J. Psychiatry 156, 837–841 (1999).
11. Stoud, C. B., Davila, J. & Moyer, A. The relationship between stress and depression in first onsets versus recurrences: a meta-analytic review. J. Abnorm. Psychol. 117, 206–213 (2008).
12. Kendler, K. S., Karkowski, L. M. & Prescott, C. A. Stressful life events and major depression: risk period, long-term contextual threat, and diagnostic specificity. Psychol. Med. 28, 661–669 (1998).
13. Silberg, J., Rutter, M., Neale, M. & Eaves, L. Genetic moderation of environmental risk for depression and anxiety in adolescent girls. Br. J. Psychiatry 179, 116–121 (2001).
14. Kendler, K. S. et al. Stressful life events, genetic liability, and onset of an episode of major depression in women. Am. J. Psychiatry 152, 833–842 (1995).
15. Arnau-Soler, A., Adams, M., Hayward, C. & Thomson, P. Genome-wide interaction analysis study of a proxy for stress-sensitivity and its prediction of major depressive disorder. PLoS One 13, e0209160 (2018).
16. Arnau-Soler, A. et al. A validation of the diathesis-stress model for depression in Generation Scotland. Transl. Psychiatry (in press).
17. Garantziotis, S. & Schwartz, D. A. Ecogenomics of respiratory diseases of public health significance. Am. Rev. Respir. Dis. 31, 37–51 (2010).
18. Ashhard, H. et al. Evidence for large-scale gene-by-smoking interaction effects on pulmonary function. Int. J. Epidemiol. 46, 894–904 (2017).
19. Moffino, N. A. & Coyle, A. J. Gene-environment interactions in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 3, 491–497 (2008).
20. Polenikov, A. V., Ivanov, V. P. & Solodilova, M. A. Genetic variation of genes for xenobiotic-metabolizing enzymes and risk of bronchial asthma: the importance of gene-gene and gene-environment interactions for disease susceptibility. J. Hum. Genet. 54, 440–449 (2009).
21. Harman, C. A. et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N. Engl. J. Med. 354, 333–342 (2006).
22. Han, J., Hankinson, S. E., Colditz, G. A. & Hunter, D. J. Genetic variation in XRC1, sun exposure, and risk of skin cancer. Br. J. Cancer 91, 1604–1609 (2004).
23. Manning, A. K. et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat. Genet. 44, 659–669 (2012).
24. Wang, L., Murk, W. & DelWan, A. T. Genome-wide gene by environment interaction analysis identifies common SNPs at 17q21.2 that are associated with increased body mass index only among asthmatics. PLoS One 10, e0144114 (2015).
25. Segert, S. et al. Genome-wide investigation of gene-environment interactions in colorectal cancer. Hum. Genet. 132, 219–231 (2013).
26. Gong, J. et al. Genome-wide interaction analyses between genetic variants and alcohol consumption and smoking for risk of colorectal cancer. PLoS Genet. 12, e1005296 (2016).
27. Poffus, L. M. et al. Genome-wide association study of gene by smoking interactions in coronary artery calcification. PLoS One 8, e74642 (2013).
28. Duncan, L. E. & Keller, M. C. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am. J. Psychiatry 168, 1041–1049 (2011).
29. Risch, N. et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301, 2462–2471 (2009).
30. Karg, K., Burmeister, M., Shedden, K. & Sen, S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 68, 444–454 (2011).
31. Bleys, D., Luyten, P., Soenens, B. & Claes, S. Gene-environment interactions between stress and 5-HTTLPR in depression: a meta-analytic update. J. Affect. Disord. 226, 339–345 (2018).
32. Peyrot, W. J. et al. Does childhood trauma moderate polygenic risk for depression? A meta-analysis of 5765 subjects from the psychiatric genomics consortium. *Biol Psychiatry* **84**, 138–147 (2018).
33. Kraft, P., Yen, Y. C., Stram, D. O., Morrison, J. & Gauderman, W. J. Exploring gene-environment interaction to detect genetic associations. *Hum. Hered.* **63**, 111–119 (2007).
34. Dunn, E. C. et al. Genome-wide association study (GWAS) and genome-wide by environment interaction study (GWEx) of depressive symptoms in African American and Hispanic/Latina women. *Depress. Anxiety* **33**, 265–280 (2016).
35. Ottowa, T. et al. The first pilot genome-wide gene-environment study of depression in the Japanese population. *PLoS One* **11**, e0168023 (2016).
36. Ilieca, M. et al. Genome-wide interaction between depression and stressful life events. *J Clin Psychiatry* **77**, e29–e30 (2016).
37. Plomin, R., DeFries, J. C. & Loehlin, J. C. Genotype-environment interaction and correlation in the analysis of human behavior. *Psychol. Bull* **84**, 309–322 (1977).
38. Clarke, T. et al. Genetic and environmental determinants of stressful life events and their overlap with depression and neuroticism (version 1; referees: 3 approved with reservations). *Wellcome Open Res* **3**, 11 (2018).
39. Burgaerts, T., Bel, K. L., Whiton, P., Tennant, C. & Hurry, J. The list of threatening experiences: a subset of 12 life event categories with considerable long-term contextual threat. *Psychol. Med.* **15**, 189–194 (1985).
40. Kendler, K. S., Karkowski, L. M. & Prescott, C. A. The assessment of dependence in the study of stressful life events: validation using a twin design. *Psychol. Med.* **29**, 1455–1460 (1999).
41. Plomin, R., Lichtenstein, P., Pedersen, N. L., McClearn, G. E. & Nesselroade, J. R. Genetic influence on life events during the last half of the life span. *Psychol. Aging* **5**, 25–30 (1990).
42. Power, R. A. et al. Estimating the heritability of reporting stressful life events captured by common genetic variants. *Psychol. Med.* **43**, 1966–1971 (2013).
43. Bemmel, H. R., Bunt, S. A., Legrand, L. N., Iacona, W. G. & McGue, M. The heritability of life events: an adolescent twin and adoption study. *Twin Res. Hum. Genet.* **11**, 257–265 (2008).
44. Boardman, J. D., Alexander, K. B. & Stallings, M. C. Stressful life events and depression among adolescent twin pairs. *Biodemography Soc. Biol.* **57**, 53–66 (2011).
45. Saller, M. R. Life event, stress and illness. *Malays. J. Med. Sci.* **15**, 9–18 (2008).
46. Thanapalakul, P., Ittazakul, F., Wangprapaknon, P., Wisajuny, P. & Jullaigste, S. Psychiatric comorbidities in patients with major depressive disorder. *Neuropsychiatr. Dis. Treat.* **10**, 2097–2103 (2014).
47. Mousavi, S. et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet* **370**, 851–858 (2007).
48. Topić, R. et al. Somatic comorbidity, metabolic syndrome, cardiovascular risk, and CRP in patients with recurrent depressive disorders. *Croat. Med. J.* **54**, 453–459 (2013).
49. Lloyd, C. E., Roy, T., Nouwen, A. & Chauhan, A. M. Epidemiology of depression in diabetes: international and cross-cultural issues. *J. Affect Disord* **142**(Suppl), S22–S29 (2012).
50. Ohayon, M. M. & Schatzberg, A. F. Using chronic pain to predict depressive morbidity in the general population. *Arch. Gen. Psychiatry* **60**, 39–47 (2003).
51. Slavich, G. M. & Irwin, M. R. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. *Psychol. Bull* **140**, 774–815 (2014).
52. Smith, B. H. et al. Cohort profile: Generation Scotland: Scottish Family Health Study (GSSSFHS). The study, its participants and their potential for genetic research on health and illness. *Int. J. Epidemiol.* **42**, 689–700 (2013).
53. Szatmari, P., Szilágyi, P., O'Connell, M., Neelin, V., Knapp, M., Yannoni, C., Spain, D., Groom, A. & Afifi, T. O. Exploring brain-based genetic associations using a novel pipeline approach. *BMC Medicine* **11**, 207 (2013).
54. Kerr, S. M. et al. Genotype-phenotype interaction analyses—LTE and its association with psychosocial factors and mental disorders including its different scoring methods. *J. Affect Disord* **150**, 931–940 (2013).
55. Goldberg, D. P. & Hillier, V. F. A scaled version of the general health questionnaire. *Psychol. Med.* **9**, 139–145 (1979).
56. Sterling, M. General health questionnaire — 28 (GHQ-28). *J. Physiother.* **57**, 259 (2011).
57. Goldberg, D. P. et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. *Psychol. Med.* **27**, 191–197 (1997).
58. Wang, L. et al. [Value of patient health questionnaires (PHQ)—9 and PHQ-2 for screening depression disorders in cardiovascular outpatients]. *Zhonghua Xin Xue Guan Bing Za Zhi* **43**, 428—431 (2015).
59. Spitzer, R. L., Kroenke, K. & Williams, J. B. Validation and utility of a self-report version of PRIME-MD: the PHQ-2 primary care study. Primary care evaluation of mental disorders. *JAMA* **282**, 1737–1744 (1999).
60. Smith, D. J. et al. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. *PLoS One* **8**, e75362 (2013).
61. Liu, J. Z., Erlich, Y. & Pickrell, J. K. Case-control association mapping by proxy using family history of disease. *Nat. Genet.* **49**, 325–331 (2017).
62. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
63. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet* **81**, 559–575 (2007).
64. Almli, L. M. et al. Correcting systematic inflation in genetic association tests that consider interaction effects: application to a genome-wide association study of posttraumatic stress disorder. *JAMA Psychiatry* **71**, 1392–1399 (2014).
65. Keller, M. C. Gene x environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. *Biol Psychiatry* **75**, 18–24 (2014).
66. Watanabe, K., Taskesen, E., van Bochove, A. & Posthuma, D. FUMA: functional mapping and annotation of genetic associations. *Nat. Commun.* **8**, 1826 (2017).
67. Euesden, J., Lewis, C. M. & O'Reilly, P. F. PRSice: polygenic risk score software. *Bioinformatics* **31**, 1466–1468 (2015).
68. Cross-Disorder Group of the Psychiatric Genomics et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat. Genet.* **45**, 984–994 (2013).
69. Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat. Commun.* (in press).
70. Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. *BMJ* **323**, 1080 (2006).
71. Stein, J. L. et al. Voxelwise genome-wide association study (vGWAS). *Neuroimage* **53**, 1160–1174 (2010).
72. Hart, A. B. et al. Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). *PLoS One* **7**, e42646 (2012).
73. Sugimoto, K. et al. The induction of H3K9 methylation by PIWIL4 at the HSD11B3 locus. *Biochem. Biophys. Res. Commun.* **359**, 497–502 (2007).
74. Sivagurunathan, S., Arunachalam, J. P. & Chidambaram, S. PIWI-like protein, HWA2 is aberrantly expressed in retinoblastoma cells and affects cell-cycle potentially through OTX2. *Cell. Mol. Biol. Lett.* **22**, 17 (2017).
86. Lee, H. H. C. et al. Genetic Oto2 mis-localization delays critical period plasticity across brain regions. *Mol. Psychiatry* **22**, 680–688 (2017).
87. Sonuga-Barke, E. J. et al. Does parental expressed emotion moderate genetic effects in ADHD? An exploration using a genome wide association scan. *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* **147B**, 1359–1368 (2008).
88. Belzeaux, R. et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. *Transl. Psychiatry* **2**, e185 (2012).
89. Mamdani, F., Berlim, M. T., Beaulieu, M. M. & Turecki, G. Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder. *World J. Biol. Psychiatry* **15**, 135–144 (2014).
90. Wong, M. L. et al. The PHF21B gene is associated with major depression and modulates the stress response. *Mol Psychiatry* **22**, 1015–1025 (2017).
91. Walsh, R. M. et al. Phf8 loss confers resistance to depression-like and anxiety-like behaviors in mice. *Nat. Commun.* **8**, 15142 (2017).
92. Shi, G. et al. PHD finger protein 2 (PHF2) represses ribosomal RNA gene transcription by antagonizing PHF finger protein B (PHF8) and recruiting methyltransferase SUV39H1. *J. Biol. Chem.* **289**, 29691–29700 (2014).
93. Yu, D. et al. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette’s syndrome and OCD. *Am. J. Psychiatry* **172**, 82–93 (2015).
94. Eaves, L. J., Last, K., Martin, N. G. & Jinks, J. L. A progressive approach to non-additivity and genotype-environmental covariance in the analysis of human differences. *Br. J. Math. Stat. Psychol.* **30**, 1–42 (1977).
95. Polderman, T. J. et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. *Nat. Genet.* **47**, 702–709 (2015).
96. Ceccato, S., Kudielka, B. M. & Schwieren, C. Increased risk taking in relation to chronic stress in adults. *Front. Psychol.* **6**, 2036 (2015).
97. Kandler, C., Bliedorn, W., Riemann, R., Angleitner, A. & Spinath, F. M. Life events as environmental states and genetic traits and the role of personality: a longitudinal twin study. *Behav. Genet.* **42**, 57–72 (2012).
98. Conway, C. C., Hammen, C., Brennan, P. A., Lind, P. A. & Najman, J. M. Interaction of chronic stress with serotonin transporter and catechol-O-methyltransferase polymorphisms in predicting youth depression. *Depress Anxiety* **27**, 737–745 (2010).
99. Cicchetti, D. & Rogosch, F. A. Genetic moderation of child maltreatment effects on depression and internalizing symptoms by serotonin transporter linked polymorphic region (5-HTTLPR), brain-derived neurotrophic factor (BDNF), norepinephrine transporter (NET), and corticotropin releasing hormone receptor 1 (CRHR1) genes in African American children. *Dev. Psychopathol.* **26**, 1219–1239 (2014).